Free Trial

DBV Technologies Q4 2024 Earnings Report

DBV Technologies logo
$7.32 +0.13 (+1.81%)
Closing price 04/11/2025 04:00 PM Eastern
Extended Trading
$7.28 -0.04 (-0.55%)
As of 04/11/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DBV Technologies EPS Results

Actual EPS
-$1.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
$0.51 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Tuesday, April 15, 2025
Conference Call Time
12:40PM ET

Upcoming Earnings

DBV Technologies' Q4 2024 earnings is scheduled for Tuesday, May 6, 2025

Remove Ads

Earnings Documents

DBV Technologies Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More DBV Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email.

About DBV Technologies

DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

View DBV Technologies Profile

More Earnings Resources from MarketBeat